SCHEMBL751265

SCHEMBL751265

Cc1n[c]cc(Nc2ccncn2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.40
CDK9 P50750 1/20 0.40
CDK5 Q00535 1/20 0.40
TAOK1 Q7L7X3 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
TGFBR1 P36897 2/20 0.36
KDR P35968 2/20 0.35
MKNK1 Q9BUB5 8/20 0.34
CCNA2 P20248 1/20 0.34
CDK2 P24941 1/20 0.34
CCNA1 P78396 1/20 0.34
TGFBR2 P37173 1/20 0.34
FYN P06241 2/20 0.34
MKNK2 Q9HBH9 5/20 0.33
LYN P07948 1/20 0.33
SRC P12931 1/20 0.33
BTK Q06187 1/20 0.33
ACP1 P24666 1/20 0.33
EIF4E P06730 1/20 0.33
MPL P40238 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750473 0.79 KMT2A (0.46) CDK9KDRCCNA2CDK2
SCHEMBL753408 0.76 KDM4E (0.36) CDK5KDRCCNA2CDK2CCNA1
SCHEMBL4630887 0.75 GSK3A (0.53) GSK3ACDK9CDK5TAOK1CLK4
Hydrochloric Acid SCHEMBL7857018 0.73 GSK3A (0.51) GSK3ACDK9CDK5TAOK1CLK4
SCHEMBL753277 0.72 GOT1 (0.41) BTK
SCHEMBL765373 0.72 TRPV4 (0.42) LYNSRCBTK
SCHEMBL750710 0.71 TRPV4 (0.43) GSK3ATGFBR1KDR
SCHEMBL750531 0.70
SCHEMBL27625398 0.69 TGFBR1 (0.53) GSK3ACDK9CDK5TAOK1CLK4
SCHEMBL29532960 0.68 GSK3A (0.49) GSK3ACDK9CDK5TAOK1CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD GSK3A 145/4885CDK9 205/4885CDK5 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.